N
TGTX icon

Natixis’s TG Therapeutics TGTX Stock Holding History

Natixis’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29
Closed -$864 – 1320
2025
Q4 		$864 Buy
+29
New +$947 ﹤0.01% 1086

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Natixis's TGTX Position: Q1 2026 in Review

Natixis sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 29 shares — an estimated $864 sold.

Natixis first reported a position in TGTX in Q4 2025 and held it in 1 quarter. The position peaked at $864 in Q4 2025. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Natixis reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 29 TG Therapeutics shares in Q1 2026, an estimated $864.
  • Natixis first reported a position in TG Therapeutics in Q4 2025 and held it in 1 quarter.
  • Natixis's TG Therapeutics position peaked at $864 in Q4 2025.
  • 365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.